Swiss Healthcare Policy: Cost Shifting Instead of Structural Reform – A Liberal Critique
Summary
In the 2026 spring session, the Swiss Parliament advanced two healthcare policy measures: The increase of the minimum deductible from 300 to 400 francs (consultation since March 13, 2026, Motion Friedli 24.3636) and the introduction of an optional emergency fee of 50 francs (National Council, 96:91 votes, March 18, 2026). Both instruments shift costs to the demand side – to patients. Structural reforms on the supply side – reference price system, coordination models, tariff adjustments – remain politically blocked. Basic insurance paid a total of 42.2 billion francs for medical services in 2024.
Persons
- Esther Friedli (SVP Council of States member, author of Motion 24.3636)
- Patrick Hässig (GLP National Councillor, initiator of the emergency fee)
- Elisabeth Baume-Schneider (Health Minister, rejected the emergency fee)
Topics
- Cost containment and personal responsibility
- Deductible policy and premium development
- Emergency medicine and steering levies
- Lobby asymmetry in healthcare
- Supply reforms vs. demand management
Clarus Lead
Both proposals show a common pattern: Parliament chooses the path of least political resistance. Deductibles and emergency fees burden all insured persons diffusely, while structural interventions with healthcare providers and the pharmaceutical industry have been failing for years due to organized counter-interests. From a liberal perspective, the result is paradoxical: Both measures interfere with individual health decisions but create no functioning market – because they establish neither price transparency nor genuine competition. The cost savings from the deductible increase (barely 300 million CHF) corresponds to less than one percent of total OKP costs – while additional cost growth amounts to 2.3 billion francs between 2023 and 2024 alone.
Detailed Summary
Fact Check: What's Accurate, What's Not?
The clarus.news article on the deductible increase refers to the BAG efficiency study as a "federal office study from 2020." Correct is: The study by INFRAS and Zurich University of Applied Sciences was published in 2019 and is based on data from 2016. The magnitude of 7 to 8.4 billion francs efficiency potential (16–19 percent of OKP services) is confirmed by NZZ and Beobachter. However, the BAG stated it cannot quantify how much of this has been realized since then. The figure has thus lost precision over a decade.
The claim that Swiss generics cost double compared to abroad is supported by the Price Supervisor and BAG data. For the 20 highest-revenue active ingredients, the surcharge averages 165 percent compared to 15 European comparison countries according to the Price Supervisor. The National Council rejected the reference price system in October 2020, the Council of States confirmed this in December 2021 – not in 2026, as the chronology in the article suggests.
Regarding the emergency fee: The voting result (96:91, 3 abstentions) and the coalition (GLP, FDP, SVP in favor; Center, SP, Greens against) are correct. However, the clarus.news article does not mention that the Federal Council, the majority of cantons, and the hospital association H+ explicitly reject the fee. This omission weakens the analytical depth, as rejection by implementation actors is central to evaluating effectiveness.
The Liberal Core Question: Incentives or Alibi?
A functioning healthcare system needs price signals. The deductible increase of 100 francs sends a weak signal: For chronically ill and older insured persons – 45 percent of adults choose the minimum deductible – the incentive structure barely changes because they exhaust their deductible anyway. It merely shifts 100 francs per year from solidarity financing to direct burden. The actual liberal lever – competition on the supply side through reference prices, parallel imports, performance-based pharmacy remuneration – was systematically defused.
The emergency fee illustrates the same problem in mirror image: The 50 francs is designed as a steering levy, but without definition of "trivial case" (this criterion already failed implementation in 2017), the fee becomes a flat rate. Hospital association H+ calls it "impractical and ineffective". Cantonal freedom of choice in implementation creates fragmentation – and the risk of canton shopping, which SP National Councillor Farah Rumy warns against.
What's Missing: The Hidden Reform Agenda
At the Cost Containment Round Table (November 2024), cantons, doctors, hospitals, insurers, and pharma agreed on 38 measures with annual savings potential of around 300 million francs. For comparison: OKP costs rose to 42.2 billion francs in 2024 – the savings correspond to 0.7 percent. Medication costs alone were 9.2 billion francs in 2024, an increase of 15 percent above the average of other services. A reference price system would have brought 300 to 500 million francs annually according to Federal Council estimates – but was blocked by a coalition of SVP National Councillor Thomas de Courten (simultaneously president of the Intergenerika association) and pharma lobbyists.
Key Messages
- Both measures (deductible +100 CHF, emergency fee 50 CHF) shift costs to the demand side without forcing structural efficiency gains.
- The savings (ca. 300 million CHF through deductibles) are marginal compared to cost growth (+2.3 billion CHF in one year) and identified efficiency potentials (7–8.4 billion CHF).
- Parliament systematically blocks supply reforms (reference price system, coordination models) that would burden organized service providers.
- The emergency fee is rejected by the Federal Council, cantons, and hospital association H+ and threatens to fail at cantonal implementation.
Critical Questions
Evidence/Data Quality: The 2019 INFRAS/ZHAW study estimates efficiency potential at 7–8.4 billion CHF, yet the BAG still cannot quantify how much has been realized. Is this figure still a suitable compass for reform policy?
Conflicts of Interest: SVP National Councillor Thomas de Courten led parliamentary opposition against the reference price system while simultaneously being president of Intergenerika, the generic manufacturers' industry association. How does the parliamentary ethics commission evaluate such dual roles in votes with direct financial relevance?
Causality: The deductible increase assumes that higher cost-sharing leads to fewer unnecessary doctor visits. The 2019 OECD study shows Switzerland ranks 25th out of 34 countries with 4.3 doctor visits per person. Where exactly is the volume reduction potential?
Equity/Side Effects: 45 percent of adults – disproportionately elderly and chronically ill – have the minimum deductible. If this group exhausts their deductible anyway, the increase acts as a pure additional burden without behavioral change. Does this create an avoidance effect for prevention and early detection?
Implementability: The emergency fee already failed in 2017 due to defining "trivial case." The current solution replaces the definition with a flat rate. How should hospitals check exceptions (deductible status, pregnancy, referral) at reception in real-time without increasing administrative burden, which the Federal Council cites as the main criticism?
Conflicts of Interest (Media): The Beobachter article serving as primary source for the deductible article connects its analysis with its own petition for "premium payers' participation." Is this still independent journalism or campaign work?
Causality/Counter-hypothesis: Is the 2023–2024 cost increase (+2.3 billion CHF) primarily due to over-provision – or do demographics, inflation (passed through to tariffs for the first time in years), and benefit catalog expansions drive the dynamic?
Systemic Alternative: If the Round Table with all stakeholders could only achieve 300 million CHF in savings – is the governance of the Swiss healthcare system (corporatism with veto power for all actors) itself the structural problem?
Bibliography
Analyzed clarus.news articles:
Franchiseerhöhung in der Schweiz: Sparpaket auf dem Rücken der Vulnerablen – clarus.news, 26.03.2026
Primary sources fact check:
Bundesrat: Vernehmlassung Erhöhung Mindestfranchise – BAG, 13.03.2026
Nationalrat will 50-Franken-Gebühr beim Besuch eines Spitalnotfalls – SRF News, 18.03.2026
Schweizer Gesundheitswesen: Ruppiger Anstieg der Kosten (INFRAS/ZHAW-Studie 2019) – NZZ, 06.10.2022
Parlament lehnt Referenzpreissystem bei Generika ab – SWI swissinfo.ch, 09.12.2021
Kostenwachstum gemeinsam dämpfen (Runder Tisch 300 Mio.) – Soziale Sicherheit CHSS, 18.12.2025
Medikamentenpreise auf Rekordhoch (9,2 Mrd. CHF) – watson.ch, 30.01.2026
Verification status: ✓ 2026-03-30